Menu
Synergy in Action

5th Annual Scientific Meeting

03 – 05 March, 2009   //   Arlington, Virginia, USA

Poster Awardees

“Knowing When a Drug is Not Going to Work in Bipolar Depression”: Absence of Early Improvement as a Predictor of Later Non-Response in 3,369 Patients From 10 Placebo-Controlled Acute Trials
J Calabrese
Regional and Temporal Differences in Use of Doctorate Level MADRS Raters in Bipolar Depression Trials
D Daniel

Related Publications

AC Leon
Two Clinical Trial Designs to Examine Personalized Treatments for Psychiatric Disorders
Journal of Clinical Psychiatry (in press)

Day 1 (3 March 2009)

President’s Welcome G Gharabawi
slides
slides
SESSION 1: Development of Treatments for Bipolar Depression
SUMMARY OF SESSION
Chairs:
R Baldessarini
E Vieta
Introduction and Objectives E Vieta
Bipolar Versus Unipolar Depression R Baldessarini
slides
slides
video
Challenges to Design of Treatment Trials for Bipolar Depression: An International Perspective E Vieta
slides
slides
video
Methodological Challenges in Short-term Treatment Trials for Bipolar Depression M Tohen
slides
slides
video
Methodological Challenges in Long-term Treatment Trials for Bipolar Depression J Calabrese
slides
slides
video
Panel and General Discussion: Treatment Trials for Bipolar Depression C Bowden
slides
slides
video video
Session Discussion – Q&A video video

Day 2 (4 March 2009)

SESSION 2: Improving Methodology of RCTs for PTSD
SUMMARY OF SESSION
Chairs:
A Leon
L Davis
Introduction to Session L Davis
video
National Priorities for PTSD RCT Research T O’Leary
slides
slides
video
Consideration of PTSD Nosology and Pathophysiology in Targeting the Study Population, Intervention, and Outcomes L Davis
slides
slides
video
Psychotherapy Methodological Issues: Choice of Comparison Group A Suris
slides
slides
video
Methodology for Evaluating Moderators of PTSD Treatment A Leon
slides
slides
video
Methodological Challenges for Secondary Prevention Trials in PTSD T Neylan
slides
slides
video
Session Discussion – Q&A video video
SESSION 3: Recent FDA Decisions on Approval of Antipsychotics: A Redefinition of Risk – Benefit Assessment?
SUMMARY OF SESSION
Chairs:
L Alphs
R Anand
Introduction: Objectives of Session R Anand*
Active Controls in Antipsychotic Trials: Why Have Them? A Kalali
slides
slides
video
The Role of Active Controls for Risk-Benefit Analysis in Antipsychotic Clinical Trials: Clinical/Academic Considerations J Lieberman
slides
slides
video
Discussion video  
Challenges and Implications of Use of Active Controls in Risk-Benefit Analysis in CNS Clinical Development Programs: An Industry Perspective L Alphs
slides
slides
video
Implications of Use of Active Controls in Risk-Benefit Analysis in CNS Clinical Development Programs: Statistical Considerations A Leon
slides
slides
video
Regulatory Policy Considerations on Risk-Benefit Assessment in CNS Clinical Trials and Benefit Challenges Identified in Recent New Drug Applications for Antipsychotic Drugs T Laughren*
Requirements on Medicinal Products in the Treatment of Schizophrenia – European Perspective K Broich
slides
slides
video
Summary R Anand
Poster Session View All Poster Abstracts

Day 3 (5 March 2009)

Welcome from ASENT and ISCTM Presidents slides video R Porter
L Alphs
   
SESSION 4: Methodological Issues in Examining Cognition Across the CNS Spectrum
SUMMARY OF SESSION
Chairs:
R Keefe
S Rao
Introduction: Cognition as an Under-Explored Aspect of Multiple Disorders R Keefe
slides
slides
video
Cognitive Profiles, Assessment Challenges, and Efforts Towards Advancement in Selected Example Disorders  
  Schizophrenia: MATRICS and Beyond M Green
slides
slides
video
  Multiple Sclerosis: Psychometric Considerations and Consensus Standards R Benedict
slides
slides
video
  Epilepsy: Cognitive and Behavioral Endpoints as Primary Outcome Variables D Loring
slides
slides
video
  Bipolar Disorder: Application of Cognitive Assessment Methods K Burdick
slides
slides
video
Structured Discussion  
  Regulatory Perspective: Neurological Conditions R Katz
  Regulatory Perspective: Psychiatric Conditions T Laughren
  Panel R Benedict
K Burdick
M Green
R Katz
R Keefe
T Laughren
D Loring
G Tucker
Summary and Recommendations R Keefe
S Rao
SESSION 5: Methodological Issues In Traumatic Brain Injury
SUMMARY OF SESSION
Chairs:
A Faden
slides
slides
video
T Macek
Characterization and Changes in Civilian Populations M Lovell
slides
slides
video
Characterization and Challenges in Military Populations  
  Studies of Acute mTBI in the Combat Arena M Jaffee
slides slides
video
  Studies of Chronic Problems After mTBI K Schwab
slides
slides
video
Methodological Issues and Translational Research in TBI  
  Mechanisms of Mild TBI D Smith
slides slides
video
  Methodological Problems in TBI Trials R Bullock
slides
slides
video
Discussion Q&A video
Discussion – Q&A (continued) video
 
Summary T Macek
Dinner Symposium: Resource Allocation in Translational Neuroscience: Perspectives on Influencing the Pipeline Chairs:
R Ferziger
K Clarence-Smith
  Tom Insel, MD, NIMH slides slides  
  Janet Vergis, Janssen, A Division of Ortho-McNeil Janssen Pharmaceuticals slides slides  
  Jonathan Fleming, Oxford Biosciences slides slides  
Adjourn  
* Presentation materials have not as yet been released for publication in this forum.